导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 3.33% | 1640/4773 |
| 近一周 | -3.62% | 4843/5465 |
| 近一月 | 0.64% | 484/5421 |
| 近一季 | 2.28% | 594/5231 |
| 近半年 | -3.99% | 2677/4920 |
| 近一年 | 3.85% | 1974/4394 |
| 近两年 | 26.92% | 2412/2954 |
| 近三年 | 19.42% | 1508/2253 |
| 成立以来 | 118.96% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
4.29% 548/4961 |
-10.75% 4171/5312 |
- - |
- - |
| 2025 | 3.44% 3121/4813 |
-2.71% 2961/3635 |
2.51% 1526/4076 |
2.47% 3792/4524 |
1.23% 1465/4813 |
| 2024 | 17.59% 672/3463 |
8.20% 196/2808 |
2.19% 384/3014 |
8.71% 2728/3129 |
-2.16% 1982/3463 |
| 2023 | 5.21% 197/2656 |
5.12% 827/2280 |
0.71% 282/2385 |
4.28% 155/2515 |
-4.70% 1148/2655 |
| 2022 | -0.45% 40/2207 |
1.85% 89/1919 |
-0.72% 1650/2016 |
-2.23% 33/2113 |
0.69% 1465/2208 |
| 2021 | 22.55% 142/1822 |
6.35% 94/1255 |
10.19% 490/1330 |
5.02% 302/1466 |
-0.41% 1233/1822 |
| 2020 | 21.87% 684/1250 |
-9.64% 699/1028 |
8.02% 833/1067 |
16.83% 129/1164 |
6.87% 738/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 招商中证红利ETF VS. 长安沪深300非周期A(740101) |